<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127668</url>
  </required_header>
  <id_info>
    <org_study_id>HLS/PSWAHS/18/168</org_study_id>
    <nct_id>NCT05127668</nct_id>
  </id_info>
  <brief_title>Efficacy of AirGLovE in Difficult Venous Access</brief_title>
  <acronym>EAGLE</acronym>
  <official_title>Assessment by Ultrasound of the Degree of Venous Dilation, Comparison Between Venodilation by Airglove (TM) Versus Warm-water Immersion (WWI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glasgow Caledonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glasgow Caledonian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether Airglove™ warming device dilates upper limb veins to the same degree as&#xD;
      the warm water immersion (WWI) method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Failure to cannulate to gain intra-venous access is a common occurrence in patients&#xD;
      undergoing chemotherapy, obese patients, intravenous drug users and those with chronic&#xD;
      medical problems leading to peripheral venous collapse. Difficulty in gaining IV-access is a&#xD;
      serious medical consequence since important life-saving drugs, fluids, blood transfusions,&#xD;
      and other medication are usually given via the intravenous route. Most chemotherapy units in&#xD;
      the UK rely on venous dilation by immersing the forearm of patients with &quot;difficult to&#xD;
      cannulate veins&quot; (DTCV) into a bucket of warm water. There are however, limitations in this&#xD;
      method such as controlling water temperature and ensuring proper sterility.&#xD;
&#xD;
      A new device Airglove™ has been developed which directs warm air over the forearm in a&#xD;
      polythene sleeve causing venodilation. Preliminary studies in chemotherapy patients suggest&#xD;
      that the Airglove™ causes venodilation to the extent of the warm water immersion technique,&#xD;
      however further evidence is required with testing on normal healthy volunteers.&#xD;
&#xD;
      Aims and Objectives:&#xD;
&#xD;
      To determine whether Airglove™ warming device dilates upper limb veins to the same degree as&#xD;
      the warm water immersion (WWI) method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Actual">April 16, 2019</completion_date>
  <primary_completion_date type="Actual">April 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective cross-sectional comparative study</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigator and reviewer were masked to the results</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Name of Measurement: Change in measurement of vein diameter by ultrasound</measure>
    <time_frame>Change from baseline measurements taken within 2 minutes of the intervention</time_frame>
    <description>MEASUREMENT TOOL: GE Logic S8 multi-frequency linear-array transducer (L6-15MHz), two-dimension B-mode ultrasound</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Airglove arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on the airglove arm were subjected to warming of their forearms using the Airglove device at 38.5oC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warm-water Immersion arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on the WWI arm were subjected to warming by immersing their forearms into a bucket of warm water at 38.5oC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Airglove (TM)</intervention_name>
    <description>A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.</description>
    <arm_group_label>Airglove arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Warm-water Immersion</intervention_name>
    <description>The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound</description>
    <arm_group_label>Warm-water Immersion arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants &gt; 18 years old&#xD;
&#xD;
          -  Able to give written informed consent&#xD;
&#xD;
          -  Able to understand and complete questionnaire forms independently&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants &lt; 18 years old&#xD;
&#xD;
          -  Participants with cancer and/or undergoing chemotherapy&#xD;
&#xD;
          -  Participants with difficult to cannulate veins (DTCV)&#xD;
&#xD;
          -  Participants with lymphoedema in either hand&#xD;
&#xD;
          -  Participants with pre-existing Raynaud's disease&#xD;
&#xD;
          -  Participants with Diabetes (Type 1 &amp; 2)&#xD;
&#xD;
          -  Participants with generalised anxiety disorder&#xD;
&#xD;
          -  Participants with diagnosis of hypertension&#xD;
&#xD;
          -  Participants with any cardiovascular disease, previous stroke, episodes of DVT, recent&#xD;
             treatment for venous thromboembolism (VTE), recently administered heparin,&#xD;
             participants on warfarin or any anticoagulant treatment (including NOACs).&#xD;
&#xD;
          -  Participants not able to give written informed consent&#xD;
&#xD;
          -  Participants not able to comprehend or complete questionnaire forms independently&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glasgow Calenonian University</name>
      <address>
        <city>Glasgow</city>
        <state>South Lanarkshire</state>
        <zip>G4 0BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannulation,</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Difficult venous access</keyword>
  <keyword>Difficult venepuncture</keyword>
  <keyword>Cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT05127668/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT05127668/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT05127668/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

